Navigation Links
Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
Date:4/28/2008

SHELTON, Conn., April 28 /PRNewswire/ -- Cara Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845. The Phase 1a single-center clinical trial will evaluate the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 58 healthy male and female volunteers.

The company is also developing oral and subcutaneous formulations of CR845.

About CR845

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibits analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral administration. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus) or elicit signs of addiction in animal models. Preclinical studies also indicate that CR845 possesses anti-itch activity.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates identified as mechanistically distinct, peripherally-acting analgesics.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Cara's research and clinical studies and Cara's ability to obtain additional financing. These forward- looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
2. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
6. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
9. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)...   Arena Pharmaceuticals, Inc. (NASDAQ: ... in the ralinepag phase 2 trial.  Ralinepag is an ... for the treatment of pulmonary arterial hypertension (PAH). The ... "This marks an important step in the development ... on our pipeline," said Amit Munshi , Arena,s ...
(Date:12/7/2016)... Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty Infusion Group, a ... BioRx, MedPro Rx, and XAS Infusion Suites. To learn ... ... Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... continue to build on the work we have done, we are ...
(Date:12/7/2016)... PARK, Kan. , Dec. 7, 2016   Rx ... of West Virginia and its Public Employees Insurance ... plan members access to their innovative healthcare software, ultimately saving ... partner with PEIA and provide its members with access to ... changes or a more effective, affordable therapy can be found," ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in ... to a study appearing online in the journal Radiology. , Heart disease and brain ... significantly due to the rapidly aging population. Damage to both organs often occurs at ...
(Date:12/7/2016)... Arbor, MI (PRWEB) , ... December 07, 2016 ... ... insurance and financial consultation services from offices located in South Lyon, Dewitt, Williamston, ... to benefit a basketball coach who needs treatment for a brain tumor. , ...
(Date:12/7/2016)... ... 07, 2016 , ... AlignLife clinics nationwide are giving back to their communities ... to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife hopes to ... the world. , In exchange for generous donations, customers will receive a gift in ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... proud to announce that its fully redesigned website, which launched October 17, 2016, ... a sleek responsive design and easy-to-navigate layout. Visitors and patients can discover the ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live From ... Folio: Marketing Awards competition. Live From won in the Use of Social Media ... ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
Breaking Medicine News(10 mins):